Expert Recommendations for the Diagnosis, Treatment, and Management of Adult B-Cell Acute Lymphoblastic Leukemia in Latin America

Despite strong induction chemotherapy response rates, only 30%-40% of patients with adult B-cell acute lymphoblastic leukemia (ALL) attain long-term remission. This study analyzes ALL in Latin America (LA) and recommends diagnosis, treatment, and management protocols. The Americas Health Foundation...

Full description

Saved in:
Bibliographic Details
Published in:JCO global oncology 2023-05, Vol.9 (9), p.e2200292
Main Authors: Basquiera, Ana Lisa, Seiwald, Maria Cristina, Best Aguilera, Carlos Roberto, Enciso, Leonardo, Fernandez, Isolda, Jansen, Angela Marie, Nunes, Elenaide, Sanchez Del Villar, Matias, Urbalejo Ceniceros, Victor I, Rocha, Vanderson
Format: Article
Language:English
Subjects:
Adult
Humans
Inotuzumab Ozogamicin - therapeutic use
Latin America - epidemiology
Mexico
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
REVIEW ARTICLES
Rituximab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite strong induction chemotherapy response rates, only 30%-40% of patients with adult B-cell acute lymphoblastic leukemia (ALL) attain long-term remission. This study analyzes ALL in Latin America (LA) and recommends diagnosis, treatment, and management protocols. The Americas Health Foundation organized a panel of hematologists from Argentina, Brazil, Chile, Colombia, and Mexico to examine ALL diagnosis and therapy and produce recommendations. Lack of regional data, unequal access to diagnosis and therapy, inadequate treatment response, and uneven health care distribution complicate adult ALL management. The panel recommended diagnosis, first-line and refractory treatment, and post-transplantation maintenance. Targeted treatments, including rituximab, blinatumomab, and inotuzumab ozogamicin, are becoming available in LA and must be equitably accessed. This review adapts global information on treating ALL to LA. Governments, the medical community, society, academia, industry, and patient advocates must work together to improve policies.
ISSN:2687-8941
2687-8941
DOI:10.1200/GO.22.00292